Clinical Trials
13 trialsNCT05263050 2026-05-22
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Fox Chase Cancer Center
Phase 2 Recruiting
NCT06889493 2026-04-28
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
University of Miami
Phase 1 Recruiting
NCT06638931 2026-04-15
ANTARES
Instituto do Cancer do Estado de São Paulo
Phase 2 Recruiting
NCT04079712 2026-04-13
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04969887 2026-02-27
MOST-CIRCUIT
Olivia Newton-John Cancer Research Institute
Phase 2 Active not recruiting
NCT03728361 2025-12-18
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT05262556 2025-08-07
NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas
Case Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT04197310 2025-01-31
Cabozantinib and Nivolumab for Carcinoid Tumors
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03980925 2025-01-13
Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT05266612 2024-08-09
Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors
Virogin Biotech Ltd.
Phase 1 Recruiting
NCT02923934 2024-07-24
A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers
Olivia Newton-John Cancer Research Institute
Phase 2 Completed
NCT03420521 2024-01-09
Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT04525638 2022-08-02
A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours
Fundación de investigación HM
Phase 2 Unknown